Recommendations are ‘call to action’ for African American inclusion in myeloma trials

February 23, 2021

4 min read

Source/Disclosures

Published by:

Disclosures: Anderson reports personal fees from and advisory board roles with Amgen, Bristol Myers Squibb, Gilead, Janssen, Pfizer, Precision Biosciences, Sanofi-Aventis and Takeda. Please see the guidelines for all other authors’ relevant financial disclosures.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

New guidance that emerged from an FDA and American Association for Cancer Research joint workshop addresses the underrepresentation of African Americans in multiple myeloma clinical trials.

Published in Blood Cancer Discovery, the recommendations are aimed at eliminating racial bias by including more African Americans — who are twice as likely as white individuals to be diagnosed with myeloma — in clinical trials. The recommendations also support using real-world data to better understand the effects of antimyeloma agents among African American patients…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close